Epigenetic gene silencing is an important mechanism in the initiation and progression of
cancer. Abnormal
DNA CpG island hypermethylation and histone modifications are involved in aberrant silencing of tumour-suppressor genes. LSD1 (
lysine-specific demethylase 1) was the first
enzyme identified to specifically demethylate H3K4 (Lys(4) of
histone H3). Methylated H3K4 is an important mark associated with transcriptional activation. The
flavin adenine dinucleotide-binding
amine oxidase domain of LSD1 is homologous with two
polyamine oxidases, SMO (
spermine oxidase) and
APAO (N(1)-acetylpolyamine oxidase). We have demonstrated previously that long-chain
polyamine analogues, the oligoamines, are inhibitors of LSD1. In the present paper we report the synergistic effects of specific oligoamines in combination with DFMO (2-difluoromethylornithine), an inhibitor of
ornithine decarboxylase, in human
colorectal cancer cells. DFMO treatment depletes natural
polyamines and increases the uptake of exogenous
polyamines. The combination of oligoamines and DFMO results in a synergistic re-expression of aberrantly silenced tumour-suppressor genes, including SFRP2 (secreted
frizzled-related protein 2), which encodes a Wnt signalling pathway antagonist and plays an anti-tumorigenic role in
colorectal cancer. The treatment-induced re-expression of SFRP2 is associated with increased H3K4me2 (di-methyl H3K4) in the gene promoter. The combination of LSD1-inhibiting oligoamines and DFMO represents a novel approach to epigenetic
therapy of
cancer.